First Public Notice of the Environmental Impact Assessment for the Demonstration Project on the Transformation and Construction of a Multi-Functional, Intelligent, Safe, Green, and High-End Active Pharmaceutical Ingredient Production Platform and Pilot-Scale Service Platform at Wuhan Zhongyou Pharmaceutical Co., Ltd.

In accordance with the Measures for Public Participation in Environmental Impact Assessment (Order No. 4 of the Ministry of Ecology and Environment, effective January 1, 2019), the relevant information on the demonstration project for the multi-functional, intelligent, safe, green, and high-end transformation of active pharmaceutical ingredients at Wuhan Zhongyou Pharmaceutical Co., Ltd., as well as the construction of a pilot-scale service platform, is hereby made public. Any citizens, legal entities, or other organizations that have comments or suggestions regarding this project or its surrounding environment are requested to submit them to the project proponent by telephone, fax, or email.
I. Name and Overview of the Construction Project
Project Name: Demonstration Project for the Transformation of Active Pharmaceutical Ingredients toward Multi-functionality, Intelligentization, Safety, Green Practices, and High-End Production, along with the Establishment of a Pilot-Scale Service Platform
Construction Address: No. 28, Chuangye Avenue, Gedian Development Zone, Ezhou City
Construction Entity: Wuhan Zhongyou Pharmaceutical Co., Ltd.
Nature of construction: Reconstruction
Total investment: RMB 238 million
Project scope and scale: An additional annual production capacity of 18 tonnes of potassium salt (QR01019) will be established; an additional annual production capacity of 1.3 tonnes of etaperen is also to be established.
Current project overview: The existing project, “Phase I of the Gedian Biopharmaceutical Industrial Base of Wuhan Zhongyou Pharmaceutical Co., Ltd. and the 50-ton-per-year expansion project for active pharmaceutical ingredients including fasudil mesylate,” passed the environmental protection completion acceptance on March 2, 2015. The total investment amounts to RMB 90 million, with a production capacity of 733 kg/year of atorvastatin calcium, 2,200 kg/year of quinapril hydrochloride, 10 tons/year of fasudil mesylate, 1 ton/year of tigecycline, 5 tons/year of sofosbuvir, 100 kg/year of entecavir, 10 tons/year of posaconazole, and 20 tons/year of ezetimibe—totaling eight products. The project involved the construction of eight new production lines along with corresponding pollution-control facilities.
Existing environmental protection measures for the project are as follows: ① Wastewater: The plant area implements separate stormwater and sewage systems. Production wastewater and initial rainwater are treated at the plant’s on-site wastewater treatment station and then, together with domestic sewage treated in septic tanks, are conveyed via the municipal sewer network to the Gedian Development Zone Wastewater Treatment Plant for further treatment; ② Exhaust gases: Boiler flue gas is treated by a double-alkali desulfurization process combined with a limestone wet scrubber for dust removal, and then discharged through a 40-meter-high stack; acidic tail gas is treated by an absorption tower followed by activated carbon adsorption and then discharged through a 15-meter-high stack; exhaust from the wastewater treatment station is treated by oxidation absorption, alkaline absorption, and activated carbon adsorption, and subsequently discharged through a 15-meter-high stack; ③ Noise: Low-noise equipment is selected and appropriately arranged to minimize noise levels; ④ Solid waste: Hazardous waste is entrusted to Hubei Tianyin Hazardous Waste Centralized Disposal Co., Ltd. for disposal, while domestic waste is handed over to the sanitation department for treatment; ⑤ Environmental management: Corresponding ground hardening and seepage prevention measures are implemented in key pollution areas and general pollution areas, discharge outlets are systematically planned and arranged, and a 1,000 m³ emergency containment pond has been constructed.
II. Name and Contact Information of the Construction Entity
Construction Entity: Wuhan Zhongyou Pharmaceutical Co., Ltd.
Contact Address: No. 28, Chuangye Avenue, Gedian Development Zone, Ezhou City
Contact: Zhang Hanbo
Contact number: 18062602768
Fax: 027-56919186
Email: zyyyjzb@qrpharma.net
III. Name of the Entity Preparing the Environmental Impact Report
Company Name: Wuhan Yuanqing Environmental Control Technology Co., Ltd.
Contact Address: Room 504, Unit 2, Building 24, Gezhouba Sun City, Gaoxin Fourth Road, East Lake High-tech Industrial Development Zone, Wuhan
Contact: Ding Min
Contact number: 18162594210
IV. Online Link to the Public Opinion Form
http://www.mee.gov.cn/xxgk2018/xxgk/xxgk01/201810/t20181024_665329.html
V. Methods and Channels for Submitting Public Comments
The public may submit completed public opinion forms and other relevant materials to the project proponent within the prescribed time limit by mail, fax, email, or any other means provided by the project proponent.
VI. Period for Public Submission of Comments
During the preparation of the draft environmental impact report for public consultation, the general public may submit comments related to the environmental impact assessment to the project proponent.
                                                                                                                             

Wuhan Zhongyou Pharmaceutical Co., Ltd.
June 24, 2020